AbbVie EBITDA 2010-2024 | ABBV

AbbVie EBITDA for the quarter ending June 30, 2024 was $6.129B, a 9.51% decline year-over-year.

  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.
  • AbbVie 2021 EBITDA was 26.445B, a 48.28% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

AbbVie EBITDA 2010-2024 | ABBV

  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.
  • AbbVie 2021 EBITDA was 26.445B, a 48.28% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$861.3B
Novo Nordisk (NVO)$592.4B
Johnson & Johnson (JNJ)$402.2B
Merck (MRK)$299.6B
AstraZeneca (AZN)$243.5B
Novartis AG (NVS)$236.5B
Pfizer (PFE)$169B
Sanofi (SNY)$144.1B
Innoviva (INVA)$1.2B